ArticleBMC complementary medicine and therapies2026
Zingiber officinale-mediated zinc oxide nanoparticles: antimicrobial activity against multidrug-resistant bacteria.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe fight against infectious diseases has transformed over the past century with the emergence of multidrug-resistant bacteria, where pathogens that exhibit resistance to multiple antibiotic classes leading to significant challenges to modern medicine. Zingiber officinale is well-documented to exhibit diverse biological activities, including strong antioxidant, antimicrobial, and anti-neuroinflammatory effects. Zinc oxide nanoparticles can be synthesized cost-effectively and are widely utilized in biomedical applications, including their use as anticancer agents and drug-delivery systems, as well as for their intrinsic antibacterial and anti-inflammatory properties. In this study, we aimed to take a combinatorial approach to investigate the antimicrobial effects of Z. officinale zinc oxide nanoparticles (ZnO NPs) against pathogenic bacteria with varying drug resistance profiles.
methodsBioactive molecules of Z. officinale confirmed via Gas Chromatography-Mass Spectroscopy analysis. Characterization of ZnO NPs was performed by Ultraviolet-visible (UV-Vis) spectrophotometry, Zetasizer analyser, Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction crystallography (XRD), and Scanning Electron Microscopy (SEM). Furthermore, the antimicrobial activities of zinc oxide nanoparticles, Z. officinale extract, and Z. officinale–mediated ZnO NPs were evaluated against pathogenic microorganisms, including Bacillus cereus ATCC 7064, methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis ATCC 29212, Listeria monocytogenes Scott A ATCC 49594, Uropathogenic Escherichia coli UTI89, Pseudomonas aeruginosa ATCC 27853, and carbapenem-resistant Klebsiella pneumoniae strains CRKP-239, CRKP-682, and CRKP-692.
resultsThe zeta sizer analysis showed that the Z. officinale-ZnO NPs had an average size of 89.09 nm, while the unloaded ZnO NPs measured 67.86 nm, confirming that both formulations were within the nanoscale range. ZnO NPs exhibited a well-defined zone of inhibition and low MIC values between 3.25 and 50 µg/ml. Biogenic ZnO NPs (42.42 ± 43.95 at 12.5 ± 100 µg/ml respectively) and Z. officinale extract (32.75 ± 40.22 at 12.5 ± 100 µg/ml respectively) revealed antioxidant potential.
conclusionThus, our results demonstrate that Z. officinale ZnO NPs demonstrate antimicrobial activity against a wide range of gram-positive and gram-negative multidrug-resistant pathogenic bacteria and can be further researched to target multidrug-resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.